Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Bopper...love you sense of humor--waiting, watching, waiting. I join you in the frustration while supporting your patience. Go SNDY!
Bopper,
Still long on SNDY. Not a share sold. Kudos to those who have turned a profit. For me? Still expecting SNDY to provide a handsome return.
Best to you!
Mammograms do not reduce breast cancer deaths,
study finds
By Bahar GholipourPublished February 12, 2014 LiveScience
http://www.foxnews.com/health/2014/02/12/mammograms-do-not-reduce-breast-cancer-deaths-study-finds/?intcmp=obnetwork
A cursory search will provide information on Asia and Europe's interest in the type of technology that Solos Endoscopy provides that overcomes the limitations of mammograms. That process/technology (endoscopy) is gaining a foothold; it has progressed from broken fibers and cumbersome lighting to successfully employed instruments. There is no stopping this trend toward mammogram alternatives.
Solos Endoscopy positioned itself to deploy this needed technology. Virtually debt free now, FDA approved products, AND CE mark on its Mammoview.
This is a stock to collect while under a penny.
Hulk, I am hard pressed to argue.
Many of your views over the long haul have been correct.
I will continue to hold SNDY shares because of the advantages that this type of technology affords women. The preventative nature of this technology speaks well for SNDY. Any increased exposure that SNDY garners via CE mark provides increased opportunity.
Though SNDY milestones have been busted, those same milestone have been attained. Management followed through. The arduous CE process showed commitment to shareholders. Subsequent sales--or the lack of--will be the determinant.
An opportunity exists here. I bought millions of shares because I believe the opportunity outweighs historical performance and manipulation.
Time will tell, my friend.
Best Fortune to All
Only one objective remains. Up to this point, SNDY has followed through with goals as stated in several investor news posts.
"Solos Endoscopy instruments are FDA approved. Solos Endoscopy intends to place the CE Mark on its entire MammoView® instrument line with proper approval which will allow the instrument line to be sold globally starting in 2014."
The above news has two parts: Gain CE Mark and then sell globally. We investors know now of the CE Mark accomplishment. Let us continue to accumulate as the final goal of increased profit comes to fruition.
Good Fortune to All
I am excited regarding SNDY.
Not that I am not (double negative...sorry) excited about life in general, but that I am excited about this stock in that there are definite possibilities here.
SNDY is:
- virtually debt free
- able to sell in Europe now
-- hired a reputable firm to make that happen
SNDY has:
- FDA approval
- CE mark
- accomplished a transparent plan
-- selling overseas is the natural progression
--- As soon as sales start overseas, I believe a buyout is certain
---- At that point, cheap shares (relatively speaking) will dissipate
There is no reason to think SNDY's progress stops now...today...or next week.
There is reason to believe that SNDY's progress continues...today...this year.
There is reason to believe that SNDY will merge or be bought out
Yes! I am excited.
Milestone attained. Congrats SNDY
The Congress of the European Association of Endoscopic Surgery is an active organization. Last year, this association completed its 21st gathering of countries from around the world whose physicians realize the health improvement possibilities of endoscopic surgery. Delegates from 80 countries attended the Vienna meeting.
SNDY potential? You bet! FDA approved? For sure! CE mark? Just attained. I will, as many others, hold my shares while anticipating increased SNDY revenues.
Best Fortune to ALL
Happy Thanksgiving Hook! To all a wonderful Thanksgiving. May next Thanksgiving prove all SNDY believers a very happy bunch.
Aqua, though I share your enthusiasm, I cannot agree the owner would have sold prior to CE mark. The owner planned, and with sweat equity worked for some time to achieve that mark. His intention was not to sell, but excel. There is something big over the CE horizon, and those that accumulate will prosper.
Agree. I took the opportunity to accumulate more.
Adding to my several M next week. GLTA
Eclappy1, what makes me feel better is that Europe will soon be open to SNDY. Also, I am impressed that SNDY fulfilled their plan to gain CE mark.
Again, for those who chose to pad their SNDY share-count at these low prices, just a couple of cents per share reaps major rewards.
Good fortune to you and other SNDY share holders.
The Hook, I certainly agree with you. Patience is the key. I believe that patience is there, and like you, I believe SNDY shows a very profitable 2014. Unlike 2013, European access provides opportunity. Any that say SNDY could only muster X profit in 2013 and, therefore, will only muster X+0 profit when Europe opens lose credibility.
Finally, SNDY's business plan and vision is coming to fruition. Increased profit will result in share price increase. For those with millions of shares, a hefty reward is in store (IMO) at only a few cents per share.
Slaz, when speaking just for me...
...I have to acknowledge that you are right. I was disappointed, but not disillusioned. The SNDY train is still heading in the right direction, but, and ironically so, a bit faster (from this point on).
Since SNDY management stated 4 months to completion, I must presume they reviewed the findings.The PR stated,
Solos Endoscopy will be certified to ISO 13485:2003, the internationally-
recognized standard for quality systems for medical device manufacturers,
once it reviews and resolves any corrective actions that were discovered
during the final audit.
IMO, this review of corrective actions means they (SNDY) have been briefed regarding deficiencies and the length of time to fix. I am surprised the "resolve any corrective actions" was the verbiage used. Corrective actions are not resolved, corrective actions are implemented to resolve identified deficiencies. What I mean to say, and perhaps it is a benign point, is that I would expect, "review and resolve any identified deficiencies", and, thus, and consequently, I don't believe their expert partners reviewed the PR (and perhaps they shouldn't).
Perhaps what the PR means is that corrective actions have been identified and will be implemented after first reviewing those identified corrective actions and improving on their granularity. This would make sense since a timeline was given to investors. Reason pales when providing a timeline without knowing what needs to be done. Thus, SNDY has been briefed by their expert partners. SNDY knows what needs to be done and is working to implement those corrective actions, and that means their expert partners are involved. That fact emboldens my confidence.
I am concerned by the four month fallout--SNDY must pay their partners (and have most likely worked that out), and a four month extension might mean increased costs.
But it comes down to what Highflier stated. He is right to have personal, increased confidence in SNDY. I know I do too.
The SNDY train jugs along in the right direction. The next and final stop is CE city. Personal investor profit will be determined by how long sight-seeing ranges.
Pennylanpam,
Tomorrow, I will add again. I thought last time would be my last add. I am very confident in SNDY's ability to follow their advertised game plan. I look forward to the audit report, the CE mark, the European exposure, the increase in sales, and the probable partnership/merger news.
Not long ago, I would have typed I look forward to phase one, phase two, report, CE mark, etc. Soon, I will type I look forward to European exposure, etc. Their game plan, as advertised to shareholders, is on track.
Obviously, I am betting with my money that this is the last time price will be this low.
Best fortune to all
I too will buy next week...
...and add to my position.
I did think we would show some green this week, but will console myself by adding more shares.
Desiring the best for everyone accumulating and/or holding...and ultimately selling.
Europe is at the razor edge of endoscopy. Much more than the U.S. Consider the following…you will see that European studies on endoscopy date back more than five years.
SNDY will be accepted and profits will ensue.
"A search of the MEDLINE database was performed for the period of July 2005 through October 2006. Improvements in the size of the endoscope, image quality, and method of sample collection for cytology are being reported. Given the rapid technological advances, most clinical studies are outdated by the time of publication. With this caveat in mind, 2 small prospective case series from Europe indicate that, in patients with nipple discharge, ductoscopy can effectively identify the location of a lesion but it is not sufficiently sensitive for the diagnosis of malignancy.
In a study from Europe, Hunerbein reported results using a new, rigid ductoscope during the evaluation of 66 patients with breast cancer and 45 patients with nipple discharge. (15) This new instrument is said to have improved optics as well as an approach for vacuum-assisted biopsy. In this case series, intraductal lesions were noted in 41% of patients with breast cancer. In addition, 16% of “normal” ducts had extensive intraductal lesions. The authors felt these results were promising and indicate that a multicenter European study is underway to further evaluate ductoscopy."
Reference for above: https://www.bcidaho.com/providers/medical_policies/Med/mp_20155.asp
Once SNDY acquires CE mark, I expect something analogous to previous European adds.
http://www.solosendoscopy.com/sndy93.pdf
Europe is more acceptable to endoscopy as evident with:
http://www.eaes.eu/home.aspx
The states of the U.S. will follow. Any argument from opponents of SNDY cannot tie current sales to projected sales. Any such correlation is flawed.
We supporters of SNDY have awakened a monster. And that monster is European acceptance and the U.S. following.
Good future for SNDY.
Highflier...time and effort on your part. Thanks!
Muff1...
...I am as happy as a camel on hump day!
SNDY's plan to go global fast approaches.
FDA approved products! CE mark. Debt risk low. Probable merger/acq. Stock price primed to move up, and move fast.
The SNDY train is primed.
Enjoy the ride!
Whether a proponent or opponent of SNDY...
...this latest report changes nothing. CE mark. Possible merger/buyout. There is profit to be had, and supporters and detractors know this.
May your profit benefit you, your family, and those unknown.
Best to you all
Hulk...within a week is quite tight. Are you factoring in the window for audit results? That may take more than a week, and I think we get another pop on positive results...<grin>...I will wait for that week, and see if you extend it about a week after the audit results.
I think any scenario is going to positive for investors. Some would like a BIG positive while others just want a positive, nevertheless, it will be positive. But, don't put me on record...just kidding.
Highflier, nice catch on the inconsistency.
Research on CE Mark Shows Consistent PPS Increase
I looked at Expert Resource's client list and concentrated on medical companies. I then expanded that research to non-medical companies. Research shows that a price per share increase occurs on CE mark.
IMO, those of us looking toward increased sales as the world opens to SNDY can anticipate even further price per share increase.
SNDY is a win-win proposition. I have decided to further invest in SNDY. It is obvious that any profit scenario is maximized with increased accumulation. I can see no scenario that suggests otherwise.
Again, my hopes are that SNDY investors will be rewarded for their DD.
The Hook,
Just read your post...<grin>. One of my hobbies is writing. I don't suggest what you posted of mine is good writing. I did enter two short story writing contests and garnered two contracts...just a goal of mine to see if I could...stopped after that to pursue my doctorate.
I do think the SNDY train stopped to refuel, and now gains steam. You, Highflier, Muff1, Vertical and others are correct (in my opinion): further green days are ahead and profit looks good.
I will be tremendously surprised if other than market movers sell at this point; the SNDY boiler is gaining tremendous pressure.
Best to you and your loved ones.
Highflier,
I don't take offense at the avoidance of my point or Slazenger's observation on PPS and merger cause-and-effect history. Please don't take my question as fear and necessarily requiring a consoling note. You are right, we both agree on the positive SNDY outlook.
Honestly, I just wanted to better understand Slazenger's modicum of pending disaster due to his contention that a merger has been exercised and, thus, PPS has...well, moved all it will move. You and I know that next week will only need a green day to disapprove his opinion. I valued Slazenger explaining to me what seems an easily dissolved, negative point on his part to keep PPS down.
I am green on SNDY. My several million pale in comparison to many on this board, but regardless, I truly hope you, others, and I are tremendously blessed with the pronounced confidence we have in SNDY.
The CE mark will open up a world to SNDY regardless of a merger. Past arguments that SNDY doesn't sell "much" in the states, thus, why will SNDY sell globally is growth-myopic and mostly irrelevant. SNDY is poised for greater success. Soon, their position will culminate in the mark of the European community <pun intended>.
I do appreciate your posts. Best to you.
Okay, looks like Slazenger and Highflier agree on a good thing. Still, Slazenger's contention is that the current share price accommodates that merger. Maybe I lost the response to Slazenger's PPS observation in Highflier's response. Either way, I anticipate good things for SNDY investors.
Slaz, interesting take. I don't remember you bringing up that before.
When a ticker symbol changes because of a merger, the company being acquired usually gives up its ticker symbol in favor of the acquirer's symbol.
"http://www.investopedia.com/ask/answers/04/022004.asp"
I am certainly not an expert on mergers, so I ask if you believe SNDY acquired EMERGO GROUP since Solos Endoscopy has retained the SNDY ticker symbol?
Please understand I am not ridiculing your opinion on this merger, just trying to better understand the logic behind it. Do you think this merger is of the type where both companies retain their ticker symbols?
If I misunderstood your post on this subject, I apologize now.
Best to SNDY investors...to include me.
Michael Dell and Richard Branson...cheers
Spoke to a friend also invested in SNDY.
We both wondered if an increase in shares would strengthen resolve among investors. Apparently, that is the case. Now that the "scare" of such an action (share increase) has passed, and considering SNDY investors exhibit increased confidence, I see the tactic of not meeting timelines may be the next warning used in this ever-closing window of opportunity to shake cheap shares out of investor's hands.
Since the CE inspection is almost upon us, and if that milestone is attained, I am curious what warning will ensue subsequent to the inspection. Perhaps it will be "they failed the inspection" and then after a successful inspection outcome, perhaps "no one wants their product." Then again, perhaps both will appear in unison. Regardless, the opportunity to pick up cheap shares will ultimately cease.
Also, I suspect a merger/acq will be the death knell to scare tactics, but then again, I continue to learn....
Good fortune to all.
The inspection is more valuable than…
…would be an immediate monetary increase for shareholders. (Let me step back for a moment) I do believe that the share price will continue to rise. I do believe that inspection day is just a data point along that non-linear path.
Stepping forward now:
IMO, what is more important is the fulfillment of another milestone in the strategic decision plan. That is what makes this inspection so very important to the company and its shareholders.
Strategic decisions that maximize expected value--to include those that lower near term earnings--are no less sound that those tactical decisions that momentarily raise near-term earnings. What is important is the motivation behind the decisions. A successful inspection (reported results) will nail down motivation, albeit, we can speculate strongly now regarding Solos Endoscopy's motivation.
What we see before our eyes is Solos Endoscopy (SNDY) apparent motivation: making and fulfilling strategic milestones that will bring incremental value of future cash flows. SNDY is proving to its shareholders that near-term impact to reported earnings (tactical) takes back seat to strategic planning. What is wonderful for all shareholders is that long-term investors see this. Shares will be gobbled up as a result, and that brings incremental value for short-term investors too.
The potential shift in competitive dynamics as a result of this strategic plan (that is playing out before our eyes) situates SNDY for success…on her own…in a partnership…or buyout. Any scenario (IMO) brings positive earnings to investors.
Highflier and others have said the same in so many words. Slaz and others have offered warnings that I myself have read to better balance my thinking. I put last any motivation on their (both sides) part...facts are important.
A non-linear, incrementally trending upward line is playing out before our eyes (rise in share price). SNDY is marching to a strategic plan that brings value in any scenario and long term investors see this. IMO, there is profit to be had. How much? I don’t know. I stopped speculating on that some time ago. Again, my thanks to others on this board who offered caution and elation regarding SNDY.
Best fortune to all.
That was good! Real good!...brought a smile to my face regardless of my position. Thanks.
I like your optimism. Three to six cents was my spread for the period after inspection and official results. For those who patiently accumulated and those who flipped and bought back in at lower prices, any multiple pennies translates to huge returns.
Best of fortune to you, me, and the other hopefuls. Like others, I think the next two weeks will be green days, and in comparison to the jump on inspection day, will pale in comparison.
Now you are scaring me... :)
I do think accumulators will try to keep the price down...maximize profit. Eventually, that sort of thing will increasingly become more difficult. I would like to see that happen now...lol...
Good fortune to all.
This morning's news displays SNDY's concerted business effort. For the investor, the question becomes: Is what we see window dressing or is it concrete progress/milestones achieved. I suppose we find material and tangible knowledge upon CE attainment this month. But, by that time, the increase in share price will allude the small investor with limited funds.
If SNDY gains CE mark, that positive cannot be refuted, and confidence that other planned milestones will come to fruition will only further positively drive share price.
Yes, the cruise ticket appear to be heading for new highs.
Best of luck to all.
Mike, thanks for the salutation. A good morning to you too. Always enjoy your uplifting posts. I sincerely hope you, others on this board, and I find some major profit through this venture.
If you are correct, and I think you are, this boat is set to sail and those not buying tickets now will shortly find those same tickets much more expensive.
To the SNDY cruise...and its passengers.
Congrats to touters and tankers.
Each one has their reasons, but the shared attribute is profit. I bought another batch of shares today. The movement surprised me considering the volume, but I attribute that to:
1) Until CE inspection, anticipation remains high
2) Upon CE inspection, anticipation will grow because of 100% success rate
3) After CE inspection, anticipation will grow for official results (100%)
4) Upon CE certification report, anticipation will grow on increased sales
5) Upon CE certification, plausible and probable merger/buyout
All five indicate many days of increase PPS.
I think the question remains at what point longs will sell part or all of their position. I congratulate all of us. May your profit benefit your families and mankind.
Morning Muff1
I am buying some more tomorrow. Yesterday we saw a couple of ticks up, and I think that trend will continue before the explosion at CE mark. This will probably be my last purchase, as I too have been accumulating (only what I could afford to lose) more than I anticipated that I would at the onset. But, how could I not? At these prices the ROE is too tempting.
With FDA and CE marks, the probability of improved sales, the possibility of a merger or buyout...well, for those that have been accumulating, a fee pennies up front, a few pennies improvement in share price, and we have the culmination of a wonderful story.
Best to you and the other SNDY investors.
Verticalmogo--correct!...will be loading again next week.
Correction: The reference company in my previous post is in the same state. Thank you.